Viking Therapeutics Unusual Options Activity

Deep-pocketed investors have adopted a bearish approach towards Viking Therapeutics VKTX, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in VKTX usually suggests something big is about to happen.

We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Viking Therapeutics. This level of activity is out of the ordinary.

The general mood among these heavyweight investors is divided, with 40% leaning bullish and 60% bearish. Among these notable options, 2 are puts, totaling $100,960, and 13 are calls, amounting to $432,401.

Latest Startup Investment Opportunities:

Predicted Price Range

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $12.0 to $125.0 for Viking Therapeutics over the last 3 months.

Volume & Open Interest Development

In today's trading context, the average open interest for options of Viking Therapeutics stands at 1617.5, with a total volume reaching 3,268.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Viking Therapeutics, situated within the strike price corridor from $12.0 to $125.0, throughout the last 30 days.

Viking Therapeutics Option Activity Analysis: Last 30 Days

Significant Options Trades Detected:

About Viking Therapeutics

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

In light of the recent options history for Viking Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.

Present Market Standing of Viking Therapeutics

• Currently trading with a volume of 1,242,378, the VKTX's price is up by 0.58%, now at $71.0.
• RSI readings suggest the stock is currently may be overbought.
• Anticipated earnings release is in 33 days.

What The Experts Say On Viking Therapeutics

5 market experts have recently issued ratings for this stock, with a consensus target price of $95.2.

• Reflecting concerns, an analyst from HC Wainwright & Co. lowers its rating to Buy with a new price target of $90.
• In a cautious move, an analyst from Stifel downgraded its rating to Buy, setting a price target of $80.
• An analyst from Oppenheimer persists with their Outperform rating on Viking Therapeutics, maintaining a target price of $116.
• An analyst from HC Wainwright & Co. has decided to maintain their Buy rating on Viking Therapeutics, which currently sits at a price target of $90.
• Maintaining their stance, an analyst from BTIG continues to hold a Buy rating for Viking Therapeutics, targeting a price of $100.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Viking Therapeutics options trades with real-time alerts from Benzinga Pro.